Clinical Characters and Outcome of Acute Myeloid Leukemia Patients on Correlation to CD200 and CD56 Expression

Studying DNA in Blood and Bone Marrow Samples From Younger Patients With Acute Myeloid Leukemia

NCT01024127 ·Status: COMPLETED

Predictive Clinical and Biological Parameters in Acute Leukemia, Myelodysplastic Syndromes and Myeloproliferative Disorders-HEMATO-BIO-IPC-2013-015

NCT02320656 ·Status: COMPLETED ·Phase: NA

Prognostic Values of Next Generation Sequencing (NGS) in Acute Myeloid Leukemia Patients With Allo-HSCT

NCT03715621 ·Status: UNKNOWN

Biomarkers in Samples of Bone Marrow From Patients With Acute Myeloid Leukemia

NCT01290107 ·Status: COMPLETED

Effect of Priming During Induction and Consolidations in Younger Acute Myeloid Leukemia (AML)

NCT00880243 ·Status: COMPLETED ·Phase: PHASE3

Risk-stratified Therapy Based on Molecular Cytogenetic Aberration and Treatment Response in AML

NCT03620955 ·Status: UNKNOWN

Biomarkers in Samples From Adult Patients With Acute Myeloid Leukemia Who Failed Existing Standard-of-Care Treatment

NCT01421862 ·Status: UNKNOWN

Transfusion in Adult Acute Myeloid Leukemia

NCT02899767 ·Status: COMPLETED

High Dose Daunorubicin Vs. Standard Dose Daunorubicin in Induction Treatment of AML

NCT00474006 ·Status: COMPLETED ·Phase: PHASE3

Prognostic Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia

NCT01245231 ·Status: COMPLETED

Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL

NCT07059156 ·Status: RECRUITING ·Phase: PHASE2/PHASE3

FLAG+Ida With G-CSF Priming for Patients Younger Than 60 Years With Resistant AML

NCT00559221 ·Status: UNKNOWN ·Phase: PHASE2

High-dose Cytarabine and Survival in AML

NCT01034839 ·Status: COMPLETED

Collection of Sequential Samples From Patients With Malignant Myeloid Hemopathy for the Study of Treatment Resistance

NCT05602168 ·Status: NOT_YET_RECRUITING ·Phase: NA

Decoding the Inflammasome Influence on Treatment Response in Acute Myeloid Leukemia

NCT06535113 ·Status: RECRUITING

D-index as a Predictor of Complication of Treatment of Patients With Acute Myeloid Leukemia

NCT06188182 ·Status: NOT_YET_RECRUITING

Immunophenotyping of Blast Cells and Immune Effector Cells in Peripheral Whole Blood and Bone Marrow Samples From AML and MDS Patients (AML)

NCT03801005 ·Status: COMPLETED

Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - The Biology and Outcome (BiO)-Project

NCT01252485 ·Status: RECRUITING

Identifying Cancer Genes in in Blood and Bone Marrow Samples From Patients With Acute Myeloid Leukemia

NCT00897182 ·Status: COMPLETED

Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)

NCT04777916 ·Status: RECRUITING

Interest of a Therapeutic Follow-up of the Cytarabine in the Acute Myeloid Leukaemia: Is There Constitutional Biomarkers

NCT03337516 ·Status: UNKNOWN ·Phase: NA

Biomarkers in Bone Marrow and Blood Samples From Older Patients With Acute Myeloid Leukemia Treated With Cytarabine-Based Therapy

NCT01169363 ·Status: COMPLETED

Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL

NCT04375683 ·Status: UNKNOWN ·Phase: PHASE3

Efficacy of HAD Induction With Intensified Cytarabine in Newly-diagnosed CEBPA Double Mutated Acute Myeloid Leukemia

NCT04415008 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

FLT3-ITD Gene Mutation and CD135 Expression in Acute Myeloid Leukemia.

NCT05383014 ·Status: UNKNOWN